Author Interviews, HPV, JAMA, OBGYNE / 16.09.2021

MedicalResearch.com Interview with: Helen Trottier Ph.D Assistant Professor, Department of Social and Preventive Medicine, Researcher, CHU Sainte-Justine Research Center Université de Montréal Montréal, Québec, Canada MedicalResearch.com: What is the background for this study? Response: We know that HPV infection can have serious consequences such as the development of cancerous lesions in the cervix. HPV infection is also very prevalent in young women of childbearing age but the possible consequences of HPV in pregnancy have been poorly studied. Some population registers around the world have shown a reduction in the risk of preterm birth with HPV mass vaccination, but we must be careful with this kind of ecological correlation. We have set up a large cohort study in pregnant women to study the association between HPV in pregnancy and preterm birth by targeting certain HPV genotypes and the duration of the infection. (more…)
Author Interviews, Brigham & Women's - Harvard, JAMA, OBGYNE, Pediatrics, Weight Research / 28.08.2021

MedicalResearch.com Interview with: Emily Oken MD MPH Professor, Harvard Medical School Professor in the Department of Population Medicine Associate Director and Advisor, Oliver Wendell Holmes Society. Professor, Department of Nutrition, Harvard School of Public Health MedicalResearch.com: What is the background for this study? What are the main findings? Response: In this study of over 11,000 mothers and children, we found that a mothers with higher weight in late pregnancy had children with poorer performance on tests of cognition and behavior in childhood and adolescence. The findings are consistent with results from studies in other populations around the world, as well as animal experiments.  This research suggests that maternal nutrition is important for child health over the long-term, and specifically provides support for mothers to try to achieve healthy weight and nutritional status during pregnancy. (more…)
Author Interviews, JAMA, OBGYNE, USPSTF, Weight Research / 03.06.2021

MedicalResearch.com Interview with: Chien-Wen Tseng, M.D., M.P.H., M.S.E.E. The Hawaii Medical Service Association Endowed Chair Health Services and Quality Research Professor, and Associate Research Director Department of Family Medicine and Community Health University of Hawaii John A. Burns School of Medicine MedicalResearch.com: What is the background for this study? What are the main findings? Response: Gaining weight during pregnancy is natural but gaining too little or too much weight can be harmful for pregnant people and their babies. For the first time, the Task Force reviewed the evidence and found that counseling pregnant people on healthy weight gain during pregnancy can lower their risk for diabetes during pregnancy, emergency cesarean deliveries, and babies born with a birth weight that is too high. Pregnant people may not know what amount of weight gain is healthy during pregnancy, or how weight gain can affect their pregnancy and baby. We recommend that clinicians offer all pregnant people counseling on healthy weight gain throughout their pregnancy for healthier, safer pregnancies. (more…)
Author Interviews, Lancet, Nutrition, OBGYNE / 22.05.2021

MedicalResearch.com Interview with: Susan E. Carlson Ph.D. Associate Dean for Research Program Director,, AJ Rice Professor Department of Dietetics and Nutrition University of Kansas Medical Center Kansas City, KS MedicalResearch.com: What is the background for this study? What are its benefits? Response: DHA is an omega-3 fatty acid. Good food sources include some types of seafood (e.g., salmon, tuna, trout) and chicken eggs. Persons in the USA and in much of the developing world consume little dietary DHA. DHA supplements in pregnancy have been linked to lower risk of preterm birth for 20 years, especially early preterm births (<34 weeks gestation). For about 10 years, prenatal supplements with about 200 mg DHA have been readily available in the USA, however, no study has asked if this amount of DHA is optimal to reduce early preterm birth. Participants were given a supplement of 1000 mg or 200 mg DHA beginning before 20 weeks gestation using an adaptive randomization that periodically assigned more participants to the group with the fewest early preterm births. (more…)
Author Interviews, Dermatology, JAMA, OBGYNE, Pediatrics / 09.05.2021

MedicalResearch.com Interview with: Niklas Worm Andersson, MD Department of Epidemiology Research Statens Serum Institut, Copenhagen Denmark  MedicalResearch.com: What is the background for this study? Response: "Findings from some previous fetal safety studies on topical corticosteroid use in pregnancy have raised concerns for an increased risk of newborns being small for gestational age or having low birth weight, in particular among pregnancies where larger amounts of potent to very potent agents have been used." (more…)
Author Interviews, COVID -19 Coronavirus, JAMA, OBGYNE, Pediatrics / 23.04.2021

MedicalResearch.com Interview with: Aris Papageorghiou MBChB, MRCOG Professor of Fetal Medicine and the Clinical Research Director Oxford Maternal and Perinatal Health Institute University of Oxford MedicalResearch.com: What is the background for this study? Response: Our study was really guided by a key question: does Covid-19 in pregnancy increase the risk of adverse maternal and neonatal outcomes as compared with pregnant women who do not have the infection? The question is highly relevant because of the known deleterious effects of other coronavirus infections in pregnancy, e.g. SARS (severe acute respiratory syndrome) and MERS-CoV (Middle East respiratory syndrome coronavirus). In order to answer this question we undertook this multinational cohort study. (more…)
Author Interviews, CMAJ, COVID -19 Coronavirus, OBGYNE / 19.03.2021

MedicalResearch.com Interview with: Nathalie Auger Professeure agrégée de clinique École de santé publique - Département de médecine sociale et preventive University of Montreal MedicalResearch.com: What is the background for this study? Response: COVID-19, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been a major public health concern. The number of infected pregnant women continues to increase. Pregnant women and infants are particularly susceptible to COVID-19 because the physiologic changes of pregnancy involve cardiovascular, respiratory, and immune changes that may alter the response to SARS-CoV-2 infection. Fetuses may be exposed to SARS-CoV-2 during critical periods of development. The nature of the association between COVID-19 and pregnancy outcomes remains unclear and meta-analyses of pregnant women with COVID-19 are lacking. (more…)
Author Interviews, Cannabis, JAMA, OBGYNE, Pediatrics / 08.03.2021

MedicalResearch.com Interview with: Erica M. Wymore, MD MPH Assistant Professor, Neonatal- Perinatal Medicine Department of Pediatrics, Section of Neonatology University of Colorado School of Medicine Children's Hospital Colorado Maya Bunik, MD, MPH  |  Professor, Pediatrics Medical Director, Child Health Clinic, Primary Care  |  Breastfeeding Management Clinic Adult and Child Consortium for Health Outcomes Research and Delivery Science (ACCORDS) School of Medicine| University of Colorado Anschutz Medical Campus Children's Hospital Colorado MedicalResearch.com: What is the background for this study? Response: Marijuana legalization has been increasing in the United States, with increasing consumption of marijuana products. Currently, the American Academy of Pediatrics (AAP), American College of Obstetricians and Gynecologists (ACOG) and Academy of Breastfeeding Medicine (ABM) do not recommend marijuana use during pregnancy or lactation due to concerning though limited data on the effects of perinatal marijuana exposure. As there has been increasing prevalence of women using marijuana during pregnancy due to legalization and perceptions of safety, we sought to determine the duration of THC excretion in breast milk among women who had evidence of marijuana use at delivery and abstained post-partum.  (more…)
Author Interviews, Heart Disease, JAMA, OBGYNE, Pediatrics / 18.02.2021

MedicalResearch.com Interview with: Amanda Marma Perak, MD, MS Assistant Professor of Pediatrics (Cardiology) and Preventive Medicine (Epidemiology) Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois 60611  MedicalResearch.com: What is the background for this study? What are the main findings? Response: The American Heart Association has formally defined cardiovascular health (CVH) based on the combination of 7 key health metrics: body mass index (weight versus height), blood pressure, cholesterol, glucose, diet, exercise, and smoking status. As we previously showed, the vast majority of pregnant women in the US have suboptimal CVH levels during pregnancy. We also showed that maternal CVH during pregnancy was associated with the risk for adverse newborn outcomes (such as high levels of body fat), but it was unknown what this might mean for longer-term offspring health. In the current study, the key finding was that mothers' CVH levels during pregnancy were associated with their offspring's CVH levels 10-14 years later, in early adolescence. For example, children born to mothers in the poorest category of CVH (representing 6% of mothers) had almost 8-times higher risk for the poorest CVH category in early adolescence, compared with children born to mothers who had ideal CVH in pregnancy. Even children born to mothers with any "intermediate" CVH metrics in pregnancy -- for example, being overweight but not obese -- had over 2-times higher risk for the poorest CVH category in early adolescence. (more…)
Fertility, OBGYNE / 17.02.2021

Not being able to have biological children is a fear most people hope they never to have to face. fertility-pregnancy-IVFAlthough we might not all have grown up knowing for sure if children were in our future, or already have our baby names picked out - James if it’s a boy Violet if it’s a girl - having the decision whether or not to have children taken away from us, due to biological issues inside our bodies, can be devastating. When trying to have children, it can of course, become very frustrating when you aren’t getting pregnant. If you find this is the case, it is recommended that you go to the doctor after one year of failing to conceive. It’s always a good idea to get tested to really understand what is happening in your body. The main signs a woman may be infertile is if her menstrual cycles are too long (35 days or more) or are too short (21 days or less). When going for fertility tests, it is good to have an idea of what to expect. For women, samples of blood will most likely be tested to check for the presence of the hormone Progesterone. For men, a semen sample is obtained for analysis, checking its quality and quantity. Sitting in a waiting room waiting for the results of yet more testing takes its toll, and it’s easy to feel helpless as the image of the life you had planned drifts further out of reach. Luckily nowadays, these results don’t have to be so final as we finally have other options. (more…)
Author Interviews, CDC, JAMA, OBGYNE / 03.02.2021

MedicalResearch.com Interview with: Jiajia Chen, PhD Division of Reproductive Health National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention, Atlanta, Georgia MedicalResearch.com: What is the background for this study? Response: Severe maternal morbidity (SMM) includes a range of serious pregnancy complications that result in significant short-term or long-term consequences to a woman’s health. Most research and prevention efforts addressing SMM focus on the delivery hospitalization, but less is known about SMM diagnosed after delivery discharge. (more…)
Author Interviews, Blood Pressure - Hypertension, NEJM, OBGYNE / 28.01.2021

MedicalResearch.com Interview with: DAVID K. TUROK, MD, MPH, FACOG ASSOCIATE PROFESSOR OF OBSTETRICS AND GYNECOLOGY CHIEF OF THE DIVISION OF FAMILY PLANNING UNIVERSITY OF UTAH MedicalResearch.com: What is the background for this study? Response: Researchers and clinicians have long known that copper intrauterine devices (IUDs) work extremely well for emergency contraception, using contraception after sex to prevent pregnancy. However, the hormonal IUD (levonorgestrel 52 mg IUD) has distinct characteristics that many people prefer. Namely, it reliably reduces or eliminates menstrual bleeding and cramping. Until now we did not know if the levonorgestrel IUD worked for emergency contraception. Now we know. In a first-of-its-kind study, our team at the University of Utah Health and Planned Parenthood Association of Utah found that hormonal IUDs were comparable to copper IUDs for use as emergency contraceptives. (more…)
Author Interviews, Infections, OBGYNE, Pharmaceutical Companies / 21.01.2021

MedicalResearch.com interview with: Dr. Stephen Brand, Chief Development Officer Mycovia Pharmaceuticals  Dr. Stephen Brand discusses the results of Mycovia’s three Phase 3 studies for recurrent vaginal yeast infections (RVVC )and what’s next for the company.  MedicalResearch.com: What is the background for these Phase 3 studies? Answer: Our Phase 3 clinical program for our oral therapy oteseconazole was comprised of three trials enrolling more than 870 patients at 176 sites across 11 different countries. Two of these trials, referred to as VIOLET were identical Phase 3 randomized, double-blind, placebo-controlled clinical trials to evaluate the safety of oteseconazole and its ability to prevent episodes of recurrent vulvovaginal candidiasis (RVVC), commonly referred to as chronic yeast infection. The trials took place over 48 weeks in subjects with an established disease history of at least three episodes of acute VVC in the past 12 months. More than 650 patients randomized at 125 sites across 11 countries. The VIOLET trials consisted of two parts: During the first part of the study which lasted two weeks after patients presented with an active VVC episode, patients were treated with three sequential 150mg doses of fluconazole. The second part consisted of 12 weeks, when the patient either took oteseconazole 150mg or a placebo once weekly (according to a random assignment), and then a 36-week follow-up period. In addition, subjects participating in the VIOLET trials in the U.S. who remained infection-free at their Week 48 visit were offered the opportunity to participate in an extension study and are being monitored for an additional 48 weeks to further define the long-term protection profile of oteseconazole. Eighty-five subjects are enrolled. The third Phase 3 study, called ultraVIOLET, was designed to complement and extend VIOLET as a 50-week randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of oteseconazole. In addition the study compared the effectiveness of oteseconazole compared to fluconazole, the current standard of care, to treat an acute VVC infection in the RVVC population. A total of 220 patients were randomized at 51 sites in the U.S. for the ultraVIOLET trial. The ultraVIOLET trial consisted of two parts: In the first part of the study RVVC subjects presenting with an active infection were randomized to receive either 2 days of dosing with oteseconazole or 3 sequential 150 mg doses of fluconazole (every 72 hours). The second part consisted of 11 weeks, when the patient took either oteseconazole or a placebo weekly (according to the random assignment from the first part of the study), and then a 37-week follow-up period. (more…)
Allergies, Author Interviews, OBGYNE, Pediatrics / 22.12.2020

MedicalResearch.com Interview with: Mia Stråvik PhD-student | Doktorand Department of Biology and Biological Engineering Division of Food and Nutrition Science Chalmers University of Technology MedicalResearch.com: What is the background for this study? Response: There is a need of research investigating the role of maternal diet during pregnancy and lactation on the baby’s allergy risk. Allergy is one of the most common chronic diseases of childhood, causing great suffering for the allergic child but also the entire family. Yet, the possibilities to cure and prevent this, in many cases life long, suffering are very limited. Previous research have indicated that maternal diet during pregnancy and lactation may affect the propensity of the child to develop an allergy, and diet is a factor you as a parent really can influence. (more…)
Author Interviews, COVID -19 Coronavirus, OBGYNE / 13.12.2020

MedicalResearch.com Interview with: Sheela Maru, MD, MPH Department of Health System Design and Global Health and Arnhold Institute for Global Health and Department of Obstetrics, Gynecology and Reproductive Science Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? Response: Universal screening for SARS-CoV-2 infection on Labor and Delivery (L&D) units is a critical strategy to manage patient and health worker safety, especially in a vulnerable high-prevalence community. We describe the results of a SARS-CoV-2 universal screening program at the L&D Unit at Elmhurst Hospital in Queens, NY, a 545-bed public hospital serving a diverse, largely immigrant and low-income patient population and an epicenter of the global pandemic. (more…)
Author Interviews, Infections, OBGYNE, Pediatrics / 26.11.2020

MedicalResearch.com Interview with: Jessica Miller PhD Postdoc Fellow Murdoch Childrens Research Institute  MedicalResearch.com: What is the background for this study? Response: Cesarean section (CS) may be a lifesaving intervention for women and babies. However, the global proportion of CS births is rapidly increasing and may not be medically justified. As CS has implications for both mother and child, the increasing rates warrant population-level analyses of potential risks. Many suggested long-term outcomes in CS-born children relate to altered immune development. It is possible that differences in the newborn microbiome by mode of birth contribute to the development of early immune responses which may influence the risk of immune-related outcomes, including infection. CS has been associated with an increased risk for specific infection-related hospitalisations, mainly lower respiratory tract and gastrointestinal infections, but it remains unclear whether CS is associated with increased risk of overall infection-related hospitalisation or only certain infection types, and whether risk differs for emergency versus elective/pre-labour CS. (more…)
Author Interviews, BMJ, Brigham & Women's - Harvard, Fertility, OBGYNE / 19.11.2020

MedicalResearch.com Interview with: Jennifer Yland Doctoral Student in Epidemiology Harvard T.H. Chan School of Public Health MedicalResearch.com: What is the background for this study? Response: Worldwide, about 22% of reproductive-aged women used hormonal contraception last year. Long-acting reversible contraceptive (LARC) methods, which include intrauterine devices (IUDs), implants, patches, and injectable contraceptives, have become increasingly popular. However, little is known about the return to fertility after use of different contraceptives, particularly LARC methods. (more…)
Author Interviews, Columbia, JAMA, OBGYNE, Weight Research / 05.11.2020

MedicalResearch.com Interview with: Marisa N. Spann, PhD, MPH Columbia University Irving Medical Center New York, New York MedicalResearch.com: What is the background for this study? Response: Prior research has demonstrated that higher maternal pre-pregnancy body mass index is associated with adverse long-term outcomes for offspring including obesity, poorer cognitive and social abilities, and increased risk of psychiatric disorders.  MedicalResearch.com: What are the main findings? Response: In this study, we investigated the association of maternal pre-pregnancy body mass index with fetal growth and neonatal functional connectivity and found that maternal pre-pregnancy BMI has a significant positive correlation with fetal weight and with greater thalamic connectivity of the brain.  (more…)
Author Interviews, Exercise - Fitness, OBGYNE, Weight Research / 30.10.2020

MedicalResearch.com Interview with: Suvi Ravi Faculty of Sport and Health Sciences University of Jyväskylä Jyväskylä, Finland MedicalResearch.com: What is the background for this study? Response: The results of studies comparing the prevalence of menstrual dysfunction in athletes and non-athletes have been inconsistent. Menstrual dysfunction can have many different causes but one of the most common in athletes is low energy availability (i.e., inadequate energy intake relative to energy expenditure). Disordered eating/eating disorder as a result of e.g. body weight dissatisfaction, which is the discrepancy between actual and desired weight, can be a risk factor for inadequate energy intake and thus could play a role in menstrual dysfunction. We studied a cohort of athletes and non-athletes, in adolescence (14-16 years) and subsequently in young adulthood (18-20 years) to determine the prevalence of menstrual dysfunction and body weight dissatisfaction. Menstrual dysfunction in our study was defined as primary amenorrhea, which is the absence of menses by the age of 15, prolonged menstrual cycle (>35 days), or secondary amenorrhea i.e., absence of menses for at least three consecutive months.  (more…)
Author Interviews, Fertility, Genetic Research, OBGYNE, Technology / 29.10.2020

MedicalResearch.com Interview with: PGT-A & ARTIFICIAL INTELLIGENCE IMPROVES PREGNANCY OUTCOMES FOR PATIENTS UNDERGOING IVF MedicalResearch.com Interview with: Michael Large, PhD Senior Director, Research at CooperGenomics CooperSurgical MedicalResearch.com: What is the background for this study? What are the main findings? Dr. Large: Independent study results, presented at the recent the American Society of Reproductive Medicine (ASRM) Virtual Scientific Congress, demonstrated a 13 percent relative increase in ongoing pregnancy and live birth rates associated with the use of CooperSurgical’s PGTaiSM 2.0 technology to screen embryos for in vitro fertilization (IVF). The single-center study was conducted by NYU Langone Fertility Center (NYULFC), part of The Prelude Network. Preimplantation Genetic Testing for aneuploidy (PGT-A) is performed on embryos produced through IVF; it provides genetic information to help identify embryos that are more likely to result in a successful pregnancy. PGTai 2.0 technology is an advancement in PGT-A testing platform that utilizes artificial intelligence to increase objectivity of this screening process. The study compared results from three next generation sequencing (NGS) genetic tests: Standard NGS, NGS with first generation artificial intelligence (PGTai 1.0 Technology Platform) and NGS with second generation artificial intelligence (PGTai 2.0 Technology Platform). The ongoing pregnancy and live birth rates significantly increased by a relative 13 percent in the PGTai 2.0 group as compared to subjective and prior methodologies. Study results also suggest that the increase in ongoing pregnancy and live births may be linked to improvements in several preceding IVF outcomes (implantation rates, clinical pregnancy rates and pregnancy loss.) MedicalResearch.com: What should readers take away from your report? Dr. Large: This research moves us an important step closer to our goal of increased live births, improved pregnancy outcomes and further reduction of multiples in pregnancy through greater confidence in single embryo transfer. An estimated 48.5 million couples – approximately 15% of couples -- are affected by infertility worldwide. 80,000 babies were born with IVF in 2017 in the United States and more than one million babies were born in the period 1987 to 2015 in the United States as a result of IVF. MedicalResearch.com: What recommendations do you have for future research this study? Dr. Large: The goal of PGT-A is to decrease risk and maximize the chances of IFV success by screening for embryos with the highest potential. This was precisely what NYULFC have observed so far with PGTai 2.0 compared to older technologies. To fully appreciate the impact that these improvements are having for patients, we’re excited to hear from additional IVF centers across the world as they utilize this technology. MedicalResearch.com: Is there anything else you would like to add? Any disclosures? Dr. Large: The study demonstrates CooperSurgical’s commitment to developing the most advanced technology in the field of genetic testing to advance reproductive medicine and help families. By applying artificial intelligence in the PGTaism2.0 technology, we leverage mathematical algorithms derived from real-world data to achieve objective embryo assessment. I am the Senior Director of Genomics Research and Development at CooperSurgical. Michael Large, PhD, is the Senior Director, Genomics Research and Development at CooperSurgical. His team recently led and continues to develop state-of-the-art analytical methods for interrogating Reproductive Genetics. Dr. Large earned his PhD in Cell and Molecular Biology from the Baylor College of Medicine and his Bachelor of Science in Cell and Molecular Biology from the University of Wisconsin – La Crosse. Michael Large, PhD Senior Director, Research at CooperGenomics CooperSurgical   MedicalResearch.com: What is the background for this study? What are the main findings? Dr. Large: Independent study results, presented at the recent the American Society of Reproductive Medicine (ASRM) Virtual Scientific Congress, demonstrated a 13 percent relative increase in ongoing pregnancy and live birth rates associated with the use of CooperSurgical’s PGTaiSM 2.0 technology to screen embryos for in vitro fertilization (IVF).[1] The single-center study was conducted by NYU Langone Fertility Center (NYULFC), part of The Prelude Network. Preimplantation Genetic Testing for aneuploidy (PGT-A) is performed on embryos produced through IVF; it provides genetic information to help identify embryos that are more likely to result in a successful pregnancy. PGTai 2.0 technology is an advancement in PGT-A testing platform that utilizes artificial intelligence to increase objectivity of this screening process. The study compared results from three next generation sequencing (NGS) genetic tests: Standard NGS, NGS with first generation artificial intelligence (PGTai 1.0 Technology Platform) and NGS with second generation artificial intelligence (PGTai 2.0 Technology Platform). The ongoing pregnancy and live birth rates significantly increased by a relative 13 percent in the PGTai 2.0 group as compared to subjective and prior methodologies. Study results also suggest that the increase in ongoing pregnancy and live births may be linked to improvements in several preceding IVF outcomes (implantation rates, clinical pregnancy rates and pregnancy loss.) (more…)
Author Interviews, Fertility, OBGYNE / 30.09.2020

MedicalResearch.com Interview with: Dr. Liron Rozenkrantz Postdoctoral Fellow Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology Program in Placebo Studies, Harvard Medical School Former PhD student at Human Olfaction Research group, Department of Neurobiology Weizmann Institute of Science Reut Weissgross Research student Human Olfaction Research group, Department of Neurobiology Weizmann Institute of Science MedicalResearch.com: What is the background for this study? Response: A pregnancy loss is not such a rare event as you would think: it is estimated that about 50% of all conceptions (or 15% of the documented pregnancies) end in spontaneous miscarriage. About 1-2% of all couples trying to conceive will experience recurrent pregnancy loss (RPL), meaning 2-3 consecutive miscarriages, and despite going through numerous clinical investigations (hormonal tests, genetics and so) - about half of these cases will remain unexplained. This devastating phenomenon leaves couples with no explanation as to why they cannot bear a child. While most research in this field is focused on the reproductive organs (mainly the uterus), hormones and genes, we set out to look for new possible routes. The literature regarding the tight connection between olfaction and reproduction, mainly by social body-odors (or pheromones), is heavily documented, especially in rodents. Body-odors emitted from males affect pubertal development of juvenile female rodents and estrus cycle, and females body odors affect other females’ fertility state. The most robust phenomenon in this relation is the Bruce effect, in which pregnant female mice who are exposed to body-odors from a non-stud male - will experience impanation failure in 80% of exposures! Since there is growing evidence for the involvement of the olfactory system in human reproduction, we asked whether the olfactory system is also involved in human reproductive disorders such as unexplained recurrent pregnancy loss (uRPL). To answer this question, we recruited 40 women experiencing uRPL and 57 matched controls (who never experienced a miscarriage, and are at similar age to the uRPL women), and compared their olfactory profile, mainly in response to men’s body-odors. (more…)
Author Interviews, Cannabis, JAMA, OBGYNE, Pediatrics / 25.09.2020

MedicalResearch.com Interview with: Sarah E. Paul, BA , Graduate Student and Ryan Bogdan, PhD, Associate Professor BRAIN Lab Washington University in St. Louis St. Louis, MO 63130 MedicalResearch.com: What is the background for this study? Sarah Paul: This study was motivated by several trends in cannabis use, its legal landscape, and people's perception of risk. As more states legalize recreational cannabis use, cannabis has become more accessible as well as more potent. Over the past couple of decades, the percentage of adolescents and adults who think that cannabis use is risky or harmful has fallen substantially. Cannabis dispensaries have been reported to actually recommend cannabis to pregnant women for the treatment of pregnancy-related nausea. And finally, between 2002/2003 and 2016/2017, the percentage of women reporting cannabis use during their pregnancies rose 106%. Given these trends and the mixed literature regarding the potential consequences associated with prenatal cannabis exposure, we aimed to comprehensively examine a range of outcomes in a large, representative sample while accounting for a host of important potentially confounding covariates. (more…)
Author Interviews, Coffee, OBGYNE / 25.08.2020

MedicalResearch.com Interview with: Professor Jack E. James, PhD Reykjavík University Reykjavík Iceland  MedicalResearch.com: What prompted this study?  Response: Chronic exposure to any chemical during pregnancy is cause for concern. There should be no exception simply because that chemical, caffeine, happens to be widely consumed. Caffeine is a habit-forming substance of no nutritional value. If anything, its widespread consumption suggests that it should be given special attention. Concern is heightened by what is known about the effects of caffeine on the human body, where it affects neural processes in the brain, including networks that control respiration and heart function. When consumed during pregnancy, caffeine readily crosses the placenta, exposing the fetus to the drug. Notably, the fetus is largely physically incapable of metabolising caffeine – that ability develops during the first year of life. Pregnancy studies have shown that caffeine can interfere with fetal heart function and oxygenation.  (more…)
Author Interviews, NEJM, OBGYNE, Surgical Research / 29.07.2020

MedicalResearch.com Interview with: Jane Daniels PhD Professor of Clinical Trials, Faculty of Medicine & Health Sciences School of Medicine University of Nottingham MedicalResearch.com: What is the background for this study? MedicalResearch.com: What are the main findings? Response: Uterine fibroids are the most common non-cancerous tumour in women of childbearing age. They are associated with heavy bleeding, lower chances of having children and reduced quality of life. Traditional surgical options were either to remove the fibroids (myomectomy) or completely remove the womb. A newer approach, known as uterine artery embolization, involves blocking the blood supply to the fibroids in the womb. Fibroids may be associated with infertility and problems during pregnancy, including miscarriage and preterm birth. As more women are having children at a later age, fibroids are becoming more of an issue for them and safe and effective fertility sparing treatments are needed. Both treatments improve quality of life, but myomectomy will provide greater benefit to women on average. MedicalResearch.com: What should readers take away from your report? Response: This study is the largest to date comparing women treated with either myomectomy or uterine-artery embolization for their fibroids. It was completed in hospitals across the UK, and included a substantial number of women of African-Caribbean ethnicity, who are more likely have bothersome fibroids, so we can be confident that the findings are important and relevant. Women, including those desiring a future pregnancy, should be provided with the evidence generated by the FEMME trial to enable to make a fully informed decision regarding their fibroid treatment. (more…)
Author Interviews, OBGYNE / 30.06.2020

MedicalResearch.com Interview with: Prof Roger Gadsby MBE Honorary Associate Clinical Professor Warwick Medical School University of Warwick MedicalResearch.com: What is the background for this study? Response: The term "morning sickness" is widely used to describe the nausea and vomiting symptoms that occur in pregnancy. Previous research has reported that symptoms can occur both before and after midday but little has been published describing the daily and weekly pattern of symptoms. MedicalResearch.com: What are the main findings? Response: Using a database of 256 women who kept daily symptom diaries from the onset of symptoms till around 7 weeks of pregnancy, the study modeled the daily symptom patterns and changes in daily patterns by week of pregnancy. Nausea occurred throughout the day. Vomiting had a defined peak in the morning, but can occur throughout the day (more…)
Abbvie, Author Interviews, OBGYNE / 16.06.2020

MedicalResearch.com Interview with: https://www.abbvie.com/   Ayman Al-Hendy, M.D., Ph.D. Investigator for the ELARIS UF-2 clinical trials Professor of Gynecology Director of Translational Research University of Illinois at Chicago   Dr. Al-Hendy discusses the recent announcement that the FDA has approved  ORIAHNN™ for the management of heavy menstrual bleeding due to uterine fibroids in pre-menopausal women. MedicalResearch.com: What is the background for this approval? Uterine fibroids, commonly referred to as uterine leiomyomas, are the most common type of non-cancerous tumor known to impact women of reproductive age (30-50 years old). In fact, studies show that uterine fibroids can occur in up to 70 percent of European American women and over 80 percent of African American women by age 50. As a result of uterine fibroids, women can experience a range of symptoms, the most common being heavy menstrual bleeding (i.e. prolonged and/or frequent bleeding), which can lead to other health effects such as anemia, fatigue, pelvic pain, urinary frequency etc. Uterine fibroid treatment recommendations have historically been based on the size and location of the fibroid(s). When treating larger and more complicated fibroids, healthcare providers have typically believed that surgery is their best course of action, which has made uterine fibroids the leading reason for the hysterectomies performed in the U.S. The FDA approval of ORIAHNN was based on improving care for uterine fibroid sufferers who have had a negative impact on their quality of life due to disruptive symptoms. What makes the approval of ORIAHNN so exciting, is that women now have an oral therapy to directly address heavy menstrual bleeding due to uterine fibroids.  (more…)
ASCO, Author Interviews, OBGYNE, Ovarian Cancer / 12.06.2020

MedicalResearch.com Interview with: Robert L. Coleman, MD, FACOG, FACS Chief Scientific Officer US Oncology Research MedicalResearch.com: What is the background for this study? Response: For years, there has been general support for surgery in patients with recurrent ovarian cancer supported by reams of retrospective studies that suggest patients live longer if they have surgery preceding chemotherapy. Suggested hypotheses from these trials were that patients most likely to benefit from the procedure were those with good performance status (could tolerate the procedure), had long platinum-free interval (surrogate for potential for chemotherapy response) and those in whom all disease could be resected. Each of these are also characteristics that would portend a good prognostic cohort in general and would likely do better than other patients without these characteristics. So there was a strong selection bias in these retrospective surveys. Thus, the call for randomized trials. GOG-213 was launched in 2007 with 2 primary endpoints: 1. Determine the impact of adding bevacizumab to paclitaxel/carboplatin in patients with platinum-sensitive recurrent ovarian cancer, and 2. Determine if surgery increases overall survival. (more…)
Author Interviews, JAMA, OBGYNE, Pediatrics / 11.06.2020

MedicalResearch.com Interview with: Colm Travers, M.D., MSPH Assistant Professor Department of Pediatrics University of Alabama at Birmingham MedicalResearch.com: What is the background for this study? Response: It is known that black mothers are much more likely to deliver preterm and low birth weight infants. The purpose of this study was to determine whether racial/ethnic disparities in care practices and outcomes were decreasing or increasing among extremely preterm infants. These are infants born from 22 to 27 weeks of gestation who have a high risk of death and major illnesses.  (more…)
Allergies, Author Interviews, JAMA, OBGYNE / 05.06.2020

MedicalResearch.com Interview with: Niklas Andersson MS Department of Epidemiology Research Statens Serum Institut Copenhagen S, Denmark MedicalResearch.com: What is the background for this study? What are the main findings? Response: Second-generation antihistamines are among the most commonly prescribed drug classes during pregnancy. Fexofenadine is a widely used antihistamine but given the limited fetal safety on the use of antihistamines during pregnancy in general, current clinical guidelines only recommend the use cetirizine and loratadine during pregnancy when needed due to a larger body of fetal safety data for these antihistamines. (more…)